Back to News
Market Impact: 0.35
Biogen And Eisai Announce Japan Approval Of LEQEMBI Pen To Treat Early Alzheimer's Disease
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Japan approved LEQEMBI Pen, a subcutaneous formulation of Biogen and Eisai's anti-amyloid beta protofibril antibody lecanemab. The approval adds a new administration route for LEQEMBI in Japan and is a modestly positive regulatory and commercialization development for both drugmakers.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
BIIB0.65
More News
- Arrowhead Pharmaceuticals at H.C. Wainwright: launch and pipeline widen
- Congress passes sweeping US sanctions bill targeting Russia
- House Passes Bill Allowing Trump Tariffs on Russian Oil Buyers
- Fed Rate Hike Looms as Retail Sales Surge
- The Fed decision, Clarity Act fails in Senate, Ford's truck prices and more in Morning Squawk
- OpenAI discloses six more instances of ’concerning’ AI model behavior